Compare MGM Resorts International (MGM) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MGM Resorts International vs TG Therapeutics Inc — how do they compare? MGM Resorts International trades at $43.98 (market cap $11.10B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: MGM Resorts International is the larger of the two by market cap, and MGM Resorts International pays a 0.03% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| MGM | TGTX | |
|---|---|---|
Market Cap | $11.10B | $7.64B |
Sector | Consumer Cyclical | Health |
52-Week High | $50.69 | $59.06 |
52-Week Low | $30.72 | $26.94 |
Enterprise Value | $38.40B | $7.84B |
Dividend Yield | 0.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MGM Resorts International (MGM) trades at $43.915, up 1.28% on the day, with a bearish technical signal and neutral oscillators. Recent Q2 2026 earnings missed estimates at $0.59 per share versus $0.63 expected, though revenue hit a record. The company faces a shareholder investigation into Barry Diller's proposed acquisition at $48.30 per share. Fundamentals show a P/E of 26.75 and net income margin of 2.4%, with revenue growth to $17.54B in 2025.
The outlook is mixed: analyst consensus targets $51.14 with 49% buy ratings, but technicals and acquisition uncertainty pose risks. Upside hinges on Las Vegas recovery and BetMGM's iGaming expansion, while margin pressures and legal probes are headwinds. Cash flow trends improved to a projected net positive $572M in 2026, supporting stability.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MGM Resorts International
MGM Resorts is the largest resort operator on the Las Vegas Strip with 35,000 guest rooms and suites, representing about one fourth of all units in the market. The company's Vegas properties include MGM Grand, Mandalay Bay, Cosmopolitan, Luxor, New York-New York, and CityCenter. The Strip contributed approximately 49% of total EBITDAR in the prepandemic year of 2019. MGM also owns U.S. regional assets, which represented 29% of 2019 EBITDAR. we estimate MGM's U.S. sports and iGaming operations are currently a mid-single-digit percentage of its total revenue. The company also operates the 56%-owned MGM Macau casinos with a new property that opened on the Cotai Strip in early 2018. Further, we estimate MGM will open a resort in Japan in 2027.
Read more on MGM →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
